Open-Label Clinical Trial on the Impact of Autologous Dendritic Cell Therapy on Albuminuria and Inflammatory Biomarkers (Interleukin-6, Interleukin-10, Tumor Necrosis Factor α) in Diabetic Kidney Disease (DKD)-Reed Biotech Ltd

HOME
PRODUCTS
TECHNOLOGY
NEWS CENTER
ABOUT US
CONTACT&PURCHASE
- Contact&Purchase
- Sales Promotion

FAQ

Open-Label Clinical Trial on the Impact of Autologous Dendritic Cell Therapy on Albuminuria and Inflammatory Biomarkers (Interleukin-6, Interleukin-10, Tumor Necrosis Factor α) in Diabetic Kidney Disease (DKD)

Publish：2025-05-21

Source：ReedBiotech

PREV：Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial NEXT：Investigation of the effect of tannic acid on doxorubicin-ınduced testicular damage and functions in a rat model

TECHNOLOGY